Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study.

Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. Am J Epidemiol. 2017 Dec 15;186(12):1329-1340 Authors: Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, Liao LM, Love J, Brinton LA, Gierach GL Abstract Comparing risk factor associations between invasive breast cancers and possible precursors may further our understanding of factors related to initiation versus progression. Accordingly, among 190,325 postmenopausal participants in the National Institutes of Health-AARP Diet and Health Study (1995-2011), we compared the association between risk factors and incident ductal carcinoma in situ (DCIS; n = 1,453) with that of risk factors and invasive ductal carcinomas (n = 7,525); in addition, we compared the association between risk factors and lobular carcinoma in situ (LCIS; n = 186) with that of risk factors and invasive lobular carcinomas (n = 1,191). Hazard ratios and 95% confidence intervals were estimated from multivariable Cox proportional hazards regression models. We used case-only multivariable logistic regression to test for heterogeneity in associations. Younger age at menopause was associated with a higher risk of DCIS but lower risks of LCIS and invasive ductal carcinomas (P for heterogeneity
Source: Am J Epidemiol - Category: Epidemiology Authors: Tags: Am J Epidemiol Source Type: research

Related Links:

Condition:   Malignant Neoplasm Interventions:   Drug: Fentanyl Sublingual Spray;   Drug: Morphine;   Other: Physical Performance Testing;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   D011471;   D064129;   D035683;   D009360;   D014408 Intervention:   Diagnostic Test: Periodic ARV7 and miRNA evaluation Sponsor:   Azienda Ospedaliero-Universitaria Careggi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Colon Cancer Intervention:   Combination Product: CAPECITABINE AND OXALIPLATIN Sponsor:   Universidad de León Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Patients With Metastatic Colorectal Cancer Interventions:   Drug: Fluoropyrimidine;   Drug: Bevacizumab Sponsor:   Centre Hospitalier Universitaire Dijon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Avelumab;   Drug: Aspirin;   Drug: Lansoprazole Sponsors:   The Christie NHS Foundation Trust;   University of Manchester Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Nutrition;   Physical Activity Interventions:   Behavioral: Intervention Physical Activity;   Other: Usual Care Sponsors:   University of North Carolina, Chapel Hill;   University of Texas Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Gastrointestinal Dysfunction;   Physiological Stress;   Cognition - Other Interventions:   Dietary Supplement: Yogurt with B. lactis and added honey;   Dietary Supplement: Yogurt with heat-inactivated B. lactis and added cane sugar Sponsors:   University of Illinois at Urbana-Champaign;   National Honey Board Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Neutropenia;   Breast Cancer Interventions:   Drug: Eflapegrastim;   Drug: Docetaxel;   Drug: Cyclophosphamide Sponsor:   Spectrum Pharmaceuticals, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Melanoma;   Non-small Cell Lung Carcinoma (NSCLC);   Renal Cell Carcinoma (RCC);   Brain Metastases Intervention:   Combination Product: LITT + Pembrolizumab Sponsors:   University of Florida;   Monteris Medical Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Author Affiliations open 1Epidemiology Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Research Triangle Park, North Carolina, USA 2Social &Scientific Systems, Inc., Durham, North Carolina, USA 3Westat, Durham, North Carolina, USA 4Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway 5Biostatistics and Computational Biology Branch, NIEHS, NIH, DHHS, Research Triangle Park, North Carolina, USA PDF Version (548 KB) Abstract About This Article Supplemental Material Bac...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
More News: Academia | Alcoholism | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Diets | Ductal Carcinoma | Epidemiology | Hormonal Therapy | Hormones | Lobular Carcinoma | Men | Menopause | National Institutes of Health (NIH) | Nutrition | Smokers | Study | Women